| CASPIAN研究: Durvalumab联合化疗为广泛期小细胞肺癌患者带来总生存期获益 |
| |
| 引用本文： | 吴雨微,赵明芳,柯娥娥. CASPIAN研究: Durvalumab联合化疗为广泛期小细胞肺癌患者带来总生存期获益[J]. 循证医学, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007 |
| |
| 作者姓名： | 吴雨微 赵明芳 柯娥娥 |
| |
| 作者单位： | 1.中国医科大学附属第一医院肿瘤内科, 沈阳 110001; 2.广东省人民医院肿瘤中心、广东省医学科学院、广东省肺癌研究所, 广州 510080 |
| |
| 摘 要： |
|
| 关 键 词： | 广泛期小细胞肺癌 Durvalumab PD-1/PD-L1抑制剂 一线治疗 |
Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised,Controlled, Open-Label,Phase 3 Trial |
| |
| WU Yu-wei,ZHAO Min-fang,KE E-e. Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised,Controlled, Open-Label,Phase 3 Trial[J]. The Journal of Evidence-Based Medicine, 2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007 |
| |
| Authors: | WU Yu-wei ZHAO Min-fang KE E-e |
| |
| Affiliation: | Reviewers'address: Medical Oncology, The First Affiliated Hospital, China Medical University, Shenyang 110001, China |
| |
| Abstract: | |
| |
| Keywords: | extensive-stage small-cell lung cancer durvalumab PD-1 or PD-L1 inhibitors first-line treatment |
|
| 点击此处可从《循证医学》浏览原始摘要信息 |
|
点击此处可从《循证医学》下载免费的PDF全文 |
|
